Todd Stawicki, Global Marketing Manager for MS Biopharma at SCIEX, offers an in-depth analysis of oligonucleotides and their role in preparing for the next pandemic Covid-19, the disease caused by SARS-CoV-2, is arguably the greatest public health threat in a generation. It has temporarily paralysed our just-in-time economy1,2 and highlighted many… Read More
Around 85% of Pfizer's small molecule products pass through Sandwich, Kent, on their journey to market. The work of the Kent site’s team helps millions of patients globally. Brian Henry, Vice President, Drug Product Design, Medicinal Sciences provides Megan Thomas, Drug Discovery World with insight into the scientific learnings of… Read More
Optima’s Laboratory Resource Management System – LRMS version 2021.1 – is reported to be a milestone incorporating a sophisticated engine that automates the scheduling process of the laboratory resources. Optima’s algorithm combines information collected in the system setting plus historical data generated to provide a scheduling proposal on the best… Read More
Two US Phase I clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. The vaccine combines live parasites with either of two widely used antimalarial drugs—an approach termed chemoprophylaxis vaccination. Read More
The Cell and Gene Therapy Catapult (CGT Catapult) is setting up offices and laboratories in Edinburgh, Scotland. With this expansion, CGT Catapult aims to provide additional, regionally focused support to the cell and gene therapy sector to accelerate product development, clinical trials and adoption. CGT Catapult Edinburgh is a collaboration… Read More
Immuno-oncology has advanced greatly through T cell-based therapeutic approaches (particularly immune checkpoint inhibitors). However, immune checkpoint inhibitors (ICIs) aren’t efficacious in all patients, and they carry risks. What are these risks? Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences speaks to Lu Rahman. Preclinical in vivo models serve as important… Read More
Last month, the AI-driven pharma-tech company, Exscientia announced that the world’s first Alzheimer’s disease (AD) drug candidate designed by artificial intelligence (AI) was entering Phase I clinical trials. This is the result of a collaboration with DSP, a Japanese pharmaceutical company. The drug candidate is being assessed for antipsychotic effects… Read More
Virtual clinical development specialist Phesi has released its analysis of the growth in recruiting clinical trial sites in China since the beginning of 2018. The analysis finds a significant rise in the number of recruiting sites in the country, with a 163% increase between January 2018 and January 2021. While… Read More
Sean Chang, Product Manager, Cell and Gene Therapy at Thermo Fisher Scientific It has been four years since the first Chimeric Antigen Receptor T-cell (CAR T) therapy drug, Kymriah1, was approved by the US Food and Drug Administration (FDA) for the treatment of B-cell acute lymphoblastic leukaemia (ALL). Since then,… Read More
Awakn Life Sciences has appointed neuroscientist and addiction researcher, Professor David Nutt as Chief Research Officer as well as announcing the filing of patent applications in the US for two next-generation novel MDMA-derived new chemical entities. This executive appointment is driven by the expansion of Awakn’s psychedelic drug and therapy… Read More
BRIM Biotechnology has announced it is preparing to initiate Phase III trials in 2022 for BRIM421. BRIM421 is a first-in-class peptide derived from BRIM’s proprietary, stem cell regenerative, Short Peptide (PDSP) technology platform, which can also be applied across multiple therapy areas and indications. Data demonstrate the drug has the… Read More
Shaping the UK into an epicentre for complex medicines is a report by the Medicines Discovery Catapult (MDC) in partnership with the CPI, which showcases the potential for the UK in developing complex medicines. The report details the potential medical and economic impact of this field, and how the UK… Read More
Marilyn Matz, CEO of Paradigm4, and Zachary Pitluk, Vice President of Life Sciences at Paradigm4, explain why scalable data science platforms are key to supporting integrated analysis of single-cell genomic data sets. As researchers approach the practical limits of flow cytometry and are challenged to simultaneously explore the thousands of… Read More
Two doses of the Oxford-AstraZeneca Covid-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains. These laboratory findings from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre are published… Read More
F-star Therapeutics has dosed the first patients in a Phase I clinical trial, with FS222, a CD137/PD-L1 bispecific antibody. IONTAS applied its proprietary technology to generate a component utilised within FS222, which was subsequently licenced to F-star. António Parada, CEO at IONTAS, commented: “We are delighted with the progress of… Read More
Optibrium has published a peer-reviewed study in Applied AI Letters, “Deep Imputation on Large-Scale Drug Discovery Data”, working alongside Takeda Pharmaceuticals’ proprietary global dataset and the Alchemite deep learning method. The study demonstrated that deep learning generates new and valuable insights on global pharma-scale, high-value and proprietary datasets. Such datasets… Read More
